Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Instagram Outage Disrupts Thousands of U.S. Users 
U.S. Stock Futures Slide as Tech Rout Deepens on Amazon Capex Shock 
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record 
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices 
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Mizuho has unveiled its January US Top Picks, spotlighting Chewy, GE Vernova, Enliven Therapeutics, Quest Diagnostics, DuPont, and Salesforce. These companies align with Mizuho’s high-conviction investment ideas, driven by expected catalysts over the next year.
Chewy earned a spot for its strong EBITDA margin expansion, supported by automation, vet-focused initiatives, and app engagement. With a $42 price target, analysts see a 17% upside for the pet retailer.
GE Vernova stands out as a key player in power generation, providing turbines and grid equipment that supply 30% of global electricity. Mizuho forecasts significant growth in natural gas power contracts by 2025, driven by rising data center demand.
Enliven Therapeutics shows promise with ELVN-001, an investigational tyrosine kinase inhibitor (TKI) demonstrating early efficacy in chronic myeloid leukemia (CML). Analysts see potential for ELVN-001 to expand into first-line treatment, bolstering its market outlook.
Quest Diagnostics appeals for its stable cash flow and growth opportunities in diagnostics, underpinned by Medicare and commercial pricing strength. Mizuho highlights its acquisition pipeline and EPS growth forecast for 2025.
DuPont’s planned split into ElectronicsCo, WaterCo, and the new DuPont is seen as a value catalyst. Analysts cite the company’s leadership in specialty materials like Kevlar and Tyvek, alongside seasonal sales recovery and electronics growth.
Salesforce rounds out the list, with Data Cloud and Agentforce technology driving productivity and revenue growth. Upcoming updates, multi-cloud deals, and margin improvements position Salesforce for continued success in digital transformation.
These additions reflect Mizuho’s strategic outlook for 2024, showcasing diverse opportunities across industries.
